Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2011

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions

Indolent Non-Hodgkin's LymphomaFollicular LymphomaSmall Lymphocytic LymphomaMarginal Zone Lymphoma

Interventions

DRUG

Idelalisib

Tablet(s) administered orally twice daily

Trial Locations (2)

Mount Sinai School of Medicine, New York

Stanford Cancer Center, Palo Alto